Volume 8, Issue 4, Pages (April 2009)

Slides:

Advertisements

Similar presentations

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Advertisements

Volume 387, Issue 10037, Pages (June 2016)

Volume 14, Issue 4, Pages (April 2013)

Volume 379, Issue 9824, Pages (April 2012)

Volume 357, Issue 9273, Pages (June 2001)

Volume 357, Issue 9265, Pages (April 2001)

Volume 357, Issue 9257, Pages (March 2001)

Volume 359, Issue 9322, Pages (June 2002)

Volume 18, Issue 6, Pages (June 2017)

Pharmacogenetics and future drug development and delivery

Volume 11, Issue 4, Pages (April 2012)

Volume 376, Issue 9734, Pages (July 2010)

Thank God for Richard Dawkins?

Long-term effects of hormone replacement therapy

Volume 10, Issue 12, Pages (December 2011)

Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD.

Meta-analysis of randomised controlled trials

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 14, Issue 4, Pages (April 2013)

Volume 377, Issue 9783, Pages (June 2011)

Volume 371, Issue 9611, Pages (February 2008)

Volume 376, Issue 9734, Pages (July 2010)

Volume 7, Issue 8, Pages (August 2008)

Volume 13, Issue 3, Pages (March 2012)

Long-term effects of hormone replacement therapy

Volume 376, Issue 9746, Pages (September 2010)

Volume 366, Issue 9486, Pages (August 2005)

Volume 14, Issue 4, Pages (April 2015)

Characteristics and survival of patients with Ebola virus infection, malaria, or both in Sierra Leone: a retrospective cohort study Matthew Waxman, MD,

Volume 12, Issue 9, Pages (September 2013)

Aspirin in the prevention of cancer – Author's reply

Volume 385, Issue 9966, Pages (January 2015)

Volume 368, Issue 9552, Pages (December 2006)

Volume 9, Issue 9, Pages (September 2008)

Volume 388, Issue 10061, Pages (December 2016)

Volume 378, Issue 9786, Pages (July 2011)

Volume 2, Issue 12, Pages (December 2015)

Volume 372, Issue 9642, Pages (September 2008)

Volume 2, Issue 6, Pages (June 2015)

Volume 10, Issue 4, Pages (April 2011)

Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled.

Volume 375, Issue 9732, Pages (June 2010)

Volume 379, Issue 9821, Pages (March 2012)

Volume 12, Issue 6, Pages (June 2013)

Volume 356, Issue 9241, Pages (November 2000)

Volume 14, Issue 9, Pages (September 2015)

Volume 9, Issue 9, Pages (September 2008)

Volume 14, Issue 11, Pages (October 2013)

Volume 12, Issue 8, Pages (August 2013)

Volume 388, Issue 10058, Pages (November 2016)

Volume 381, Issue 9868, Pages (March 2013)

Volume 15, Issue 8, Pages (July 2014)

Volume 372, Issue 9647, Pages (October 2008)

Volume 377, Issue 9764, Pages (February 2011)

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 371, Issue 9627, Pages (May 2008)

Telling it like it isn't: truth and lies in a post-9/11 world

Thank God for Richard Dawkins?

Department of Error The Lancet Volume 369, Issue 9564, (March 2007)

Low-technology approaches

Volume 375, Issue 9714, Pages (February 2010)

Volume 7, Issue 8, Pages (August 2008)

Volume 12, Issue 8, Pages (August 2013)

Volume 14, Issue 9, Pages (September 2015)

Volume 13, Issue 7, Pages (July 2014)

Volume 372, Issue 9632, Pages (July 2008)

Volume 14, Issue 7, Pages (June 2013)

Clinic attendance and disengagement of young adults with type 1 diabetes after transition of care from paediatric to adult services (TrACeD): a randomised,

Volume 371, Issue 9611, Pages (February 2008)

Volume 18, Issue 6, Pages (June 2019)

Presentation transcript:

Volume 8, Issue 4, Pages 334-344 (April 2009) Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient- preference trial John Collinge, MD, Michele Gorham, RN, Fleur Hudson, BA, Angus Kennedy, MD, Geraldine Keogh, Suvankar Pal, MRCP, Martin Rossor, MD, Peter Rudge, FRCP, Durre Siddique, PhD, Moira Spyer, PhD, Dafydd Thomas, MD, Sarah Walker, PhD, Tom Webb, BSc, Steve Wroe, MD, Janet Darbyshire, FRCP The Lancet Neurology Volume 8, Issue 4, Pages 334-344 (April 2009) DOI: 10.1016/S1474-4422(09)70049-3 Copyright © 2009 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile *Relative with symptomatic inherited prion disease or recipient of blood transfusion. †From September, 2001–June, 2002, six patients received open-label quinacrine in an initial pilot study, and from August, 2002, to March, 2004, 17 more were offered quinacrine or no quinacrine in an extended pilot study (total 23 patients). ‡One originally chose not to take quinacrine but later agreed to randomisation 9 weeks after enrolment and was allocated immediate quinacrine. The Lancet Neurology 2009 8, 334-344DOI: (10.1016/S1474-4422(09)70049-3) Copyright © 2009 Elsevier Ltd Terms and Conditions

Figure 2 Quinacrine use after initiation The Lancet Neurology 2009 8, 334-344DOI: (10.1016/S1474-4422(09)70049-3) Copyright © 2009 Elsevier Ltd Terms and Conditions

Figure 3 Survival Unadjusted survival from enrolment (A). Survival from enrolment by baseline Rankin score (B). Survival from first symptoms by type of human prion disease (C). The Lancet Neurology 2009 8, 334-344DOI: (10.1016/S1474-4422(09)70049-3) Copyright © 2009 Elsevier Ltd Terms and Conditions